Survey of non-alcoholic steatohepatitis in non-diabetic Haemodialysis patients in Beni-Suef Governorate
Ibrahima, A., Salem, M., Abdel-Rahman, M., Mohamed, T. (2022). Survey of non-alcoholic steatohepatitis in non-diabetic Haemodialysis patients in Beni-Suef Governorate. EKB Journal Management System, 3(4), 183-208. doi: 10.21608/ejmr.2022.271021
Ahmed Amin Ibrahima; Mohamed N. Salem; Mohamed Farag Abdel-Rahman; Tamer Mohamed Mohamed. "Survey of non-alcoholic steatohepatitis in non-diabetic Haemodialysis patients in Beni-Suef Governorate". EKB Journal Management System, 3, 4, 2022, 183-208. doi: 10.21608/ejmr.2022.271021
Ibrahima, A., Salem, M., Abdel-Rahman, M., Mohamed, T. (2022). 'Survey of non-alcoholic steatohepatitis in non-diabetic Haemodialysis patients in Beni-Suef Governorate', EKB Journal Management System, 3(4), pp. 183-208. doi: 10.21608/ejmr.2022.271021
Ibrahima, A., Salem, M., Abdel-Rahman, M., Mohamed, T. Survey of non-alcoholic steatohepatitis in non-diabetic Haemodialysis patients in Beni-Suef Governorate. EKB Journal Management System, 2022; 3(4): 183-208. doi: 10.21608/ejmr.2022.271021

Survey of non-alcoholic steatohepatitis in non-diabetic Haemodialysis patients in Beni-Suef Governorate

Egyptian Journal of Medical Research
Volume 3, Issue 4, October 2022, Page 183-208  XML PDF (683.77 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.271021
View on SCiNiTO View on SCiNiTO
Authors
Ahmed Amin Ibrahima1; Mohamed N. Salem1; Mohamed Farag Abdel-Rahman2; Tamer Mohamed Mohamed1
1Internal Medicine department, Faculty of Medicine, Beni-Suef University, Egypt
2Internal Medicine department, El-Fashn central hospital, Beni-Suef Governorate, Egypt
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) are global health issues all over the world, affecting about30% (NAFLD), and15% (CKD) of general people. Even, with absence of other risk factors such as overweight, diabetes and hypertension, there is force correlation between NAFLD and CKD. Objective:  The target of our study is to detect the incidence of non-alcoholic steatohepatitis between non-diabetic hemodialysis patients by measuring Controlled Attenuation Parameter (CAP) using transient elastography (TE) (Fibroscan®). Methodology: This was a cross sectional study in Beni-Suef governorate, including 1000 hemodialysis non-diabetic ESRD patients from different hemodialysis units from all the central hospitals in Beni-Suef governorate. Results: According to CAP (dB/M) there were 503(50.3%) S0, 233(23.3%) S1, 100(10.0%) S1-S2, 67(6.7%) S2,10(1.0%) S2-S3 and 87(8.7%) S3. According to liver stiffness grades there were 508(50.8%) F0, 280(28.0%) F1, 57(5.7%) F2,95(9.5%) F3 and 60(6.0%) F4. There were 508(50.8%) F0 and 492(49.2%) F1:F4 with mean 6.14 (± 3.90SD) and range (2.0 – 19.90). Conclusions: In this study we concluded that there is a high incidence of NAFLD among non-diabetic patients on regular Hemodialysis in Beni-Suef governorate, significantly correlated with increasing degree of liver stiffness.
Keywords
NAFLD; NASH; ESRD; HD; TE
References
  1. Nonalcoholic Fatty Liver Disease & NASH. National Institute of Diabetes and Digestive and Kidney Diseases. November 2016. Retrieved 7 November 2018.
  2. Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M, Mayo H, and Singal AG (2018). "Racial and Ethnic Disparities in. Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis". Clinical Gastroenterology and Hepatology. 16 (2): 198–210.e2. doi: 10.1016/j.cgh.2017.09.041. PMC 5794571. PMID 28970148.
  3. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, and Bugianesi E (2018). "Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention". Nature Reviews. Gastroenterology & Hepatology. 15 (1): 11–20. doi:10.1038/nrgastro.2017.109. PMID 28930295.
  4. Mann, J., Valenti, L., Scorletti, E., Byrne, C., & Nobili, V. (2018). Nonalcoholic fatty liver disease in children. In Seminars in liver disease (Vol. 38, No. 01, pp. 1-13).‏
  5. Friedman SL, Neuschwander-Tetri BA, Rinella M, and Sanyal AJ (2018). "Mechanisms of NAFLD development and therapeutic strategies". Nature Medicine. 24 (7): 908–922. doi:10.1038/s41591-018-0104-9. PMC 6553468. PMID 29967350.
  6. Vancells Lujan, P., Viñas Esmel, E., & Sacanella Meseguer, E. (2021). Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients, 13(5), 1442.‏
  7. European Association for the Study of the Liver (EASL); European Association for the study of Diabetes (EASD); European Association for the study of Obesity (EASO) (2016). "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". Journal of Hepatology. 64 (6): 1388–402. doi: 10.1016/j.jhep.2015.11.004. PMC 5644799. PMID 27062661.
  8. Pagana, K. D., & Pagana, T. J. (2017). Mosby's Manual of Diagnostic and Laboratory Tests-E-Book. Elsevier Health Sciences. ‏
  9. Xie, L. T., Yan, C. H., Zhao, Q. Y., He, M. N., & Jiang, T. A. (2018). Quantitative and noninvasive assessment of chronic liver diseases using two-dimensional shear wave elastography. World journal of gastroenterology, 24(9), 957.
  10. Moreno, C., Mueller, S., & Szabo, G. (2019). Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Journal of hepatology, 70(2), 273-283. ‏‏
  11. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, and Sanyal AJ (2018). "The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases". Hepatology. 67 (1): 328–357.
  12. Raziel A, Sakran N, Szold A, and Goitein D (2015). "Current solutions for obesity-related liver disorders: non-alcoholic fatty liver disease and non-alcoholic steatohepatitis" (PDF). The Israel Medical Association Journal. 17 (4): 234–8. PMID 26040050.
  13. Hadi A, Mohammadi H, Miraghajani M, and Ghaedi E (2018). "Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD". Critical Reviews in Food Science and Nutrition: 1–12. doi:10.1080/10408398.2018.1458021. PMID 29584449.
  14. Cozzolino, M., Mangano, M., Stucchi, A., Ciceri, P., Conte, F., & Galassi, A. (2018). Cardiovascular disease in dialysis patients. Nephrology Dialysis Transplantation, 33(suppl_3), iii28-iii34.
  15. Lonardo, A., Ballestri, S., Guaraldi, G., Nascimbeni, F., Romagnoli, D., Zona, S., & Targher, G. (2016). Fatty liver is associated with an increased risk of diabetes and cardiovascular disease.Evidence from three different disease models: NAFLD, HCV and HIV. World journal of gastroenterology, 22(44), 9674.
  16. Behairy, M., Elshaarawy, A., Aly, H., & Wasfy, M. (2019). Sp645 survey of non-alcoholic fatty liver disease among non-diabetic haemodialysis patients by transient elastography. Nephrology Dialysis Transplantation, 34(Supplement_1), gfz103-SP645.
  17. Wu, P. J., Chen, J. B., Lee, W. C., Ng, H. Y., Lien, S. C., Tsai, P. Y., ... & Chiou, T. T. Y. (2018). Oxidative stress and nonalcoholic fatty liver disease in hemodialysis patients. Biomed Research International, 2018.
  18. Mikolasevic, Ivana; Orlic, Lidija; Milic, Sandra; Zaputovic, Luka; Lukenda, Vesna; Racki, Sanjin (2014). Non-Alcoholic Fatty Liver Disease Proven by Transient Elastography in Hemodialysis Patients: Is It a New Risk Factor for Adverse Cardiovascular Events. Blood Purification, 37(4), 259–265. doi:10.1159/000360270.
  19. Choe, A. R., Ryu, D. R., Kim, H. Y., Lee, H. A., Lim, J., Kim, J. S., ... & Yoo, K. (2020). Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. BMC nephrology, 21(1), 1-11.
  20. Teeratorn, N., Piyachaturawat, P., Thanapirom, K., Chaiteerakij, R., Sonsiri, K., Komolmit, P., ... & Treeprasertsuk, S. (2020). Screening for non‐alcoholic fatty liver disease in community setting: A cohort study using controlled attenuation parameter‐transient elastography. JGH Open, 4(2), 245-250.
  21. Bellan, M., Rigamonti, C., Giacomini, G. M., Makmur, G., Marconi, C., Nicosia, F., ... & Pirisi, M. (2019). Liver Stiffness, Not Fat Liver Content, Predicts the Length of QTc Interval in Patients with Chronic Liver Disease. Gastroenterology research and practice, 2019.
  22. Chan, W. K., Nik Mustapha, N. R., & Mahadeva, S. (2014). Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. Journal of gastroenterology and hepatology, 29(7), 1470-1476.
Statistics
Article View: 131
PDF Download: 119